Alexion Pharma (ALXN) Tops Q3 EPS by 15c; Guides Above Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
Alexion Reports Third Quarter 2015 Results
October 29, 2015 6:30 AM EDTSoliris® (eculizumab) Net Product Sales of $665.4 Million; Increased 20% Year-on-Year Despite 9% Currency Headwinds; 29% Volume Increase Year-on-Year -
- 2015 Non-GAAP EPS Guidance Increased to $4.92 to $4.97 -
Strensiq (asfotase alfa) Approved in the United States, European Union, Japan and Canada for Hypophosphatasia (HPP)
Kanuma (sebelipase alfa) Approved in the European Union for Lysosomal Acid Lipase Deficiency (LAL-D)
Completed Enrollment in Registration Trial of Eculizumab in Refractory MG and Progressed Registration Trials in Relapsing NMO and DGF
Advanced Complement and Metabolic Pipelines, Including ALXN 1210 and SBC-103
CHESHIRE, Conn.--(BUSINESS... More
